Lymphoma Cases Flashcards

1
Q

Lymphoma dx

A
PE (waldeyer's ring)
B sxs
CBC w/ differential, CMP, LDH, uric acid
Excisional biopsy needed (bone marrow, flow cytometry)
Staging imaging (CT/PET)
EF, PFTs
Hep B
Fertility counseling
HIV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HL sxs

A
enlarging, rubbery, but not tender lymphadenopathy. Typically in the neck or chest.
Can be accompanied by 
Fatigue
FeverB
Weight lossB
Night sweatsB
Pain with EtOH
Symptoms of cytopenias
Hepatosplenomegaly
Pruritis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

_______ is a rare cancer, but in young people with cancer, it is very common.

A

Hodgkin Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

malignant cell in HL

A

reed-sternberg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Reed sternberg is a ___ cell, some are ____+

A

B cell

CD20+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bulk of HL tumor is

A

reactive tissue (background cells? = benign, but very prevalent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Classical HL types and marker

A

Nodular sclerosis (grades I and II)
Lymphocyte-rich classical
Mixed cellularity
Lymphocyte depleted

These are CD30+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Non-classical HL type and marker

A

Nodular lymphocyte predominant

CD20+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HL staging

A
Ann arbor staging:
I - single LN region
II - One side of diaphragm
III - both sides of diaphragm
IV - disseminated 

A - no systemic symptoms
B - fever, night sweats, weight loss

E - extralymphatic site
S - splenic site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HL treatment

A

intent to cure!
Localized favorable risk: ABVD x 2 then restage, involved field radiation
Stage III/IV disease: ABVD x 2 (restage then okay) -> ABVDx4 +/- XRT
ABVD x2 (restage but refractory) then intense chemo BEACOPP, autologous transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Late effects of therapy

A

Second malignancy (solid tumors ie lung and breast - risk continues to build, or leukemia - rare after 10-15 years)
Heart disease
Lung disease
Impaired fertility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HL markers

a. CD15+, CD30+, EBER+, CD20-, CD79a-, CD45-
b. CD5-, CD23-, CD19+, CD20+
c. CD5+, CD10-, CD20+, CD23-, cyclin D1+
d. CD5+, CD19+, CD20(dim), CD22−, CD23+, CD79b−

A

a. CD15+, CD30+, EBER+, CD20-, CD79a-, CD45- = HL
b. normal B cell
c. mantle
D. CLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

prognostics system for diffuse large b-cell lymphoma

A
IPI Prognostic factor:	
	Age over 60		
	Stage III/IV		
	ECOG PS 3 or 4 (more than ½ day resting)	
	Elevated LDH		
	Two or more extranodal sites		

Score 0 or 1: ‘Good’ with predicted 4-year progression-free survival of 94% and overall survival of 94%.
Score 2: ‘Intermediate’ with predicted 4-year progression-free survival of 80% and overall survival of 79%.
Score 3, 4 or 5: ‘Poor’ with predicted 4-year progression-free survival of 53% and overall survival of 55%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

prototype aggressive NHL for adults

A

Diffuse large b-cell lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

tx DLBL

A

R-CHOP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

most common indolent NHL

A

Follicular lymphoma

17
Q

cure follicular lymphoma?

A

Not curable

18
Q

follicular lymphoma cytogenetics

A

t(14;18)(q32;q21)
BCL-2–chromosome 18q21, inhibits apoptosis
IgH—chromosome 14q32
BCL-2 is translocated to chromosome 14, comes under control of IgH enhancer which leads to overexpression of BCL-2
But follicular lymphoma still primarily a diagnosis based on histology

19
Q

treatment of indolent NHL

A
Only when forced to:
‘Pushy nodes’
    Hydronephrosis
    Jaundice
    Dysphagia/stridor
Cytopenias (bone marrow failure)
B symptoms or fatigue
20
Q

Cyclin D1+

A

think mantle cell lymphoma

21
Q

tx mantle cell lymphoma

A

Indolent until it isn’t. Typically in advanced disease, use R-CHOP then autologous stem cell transplant or maintenance rituximab if not a transplant candidate.

22
Q

His example of markers in Mantle Cell lymphoma

A

CD20+ CD5+ BCL-2+ Cyclin D1

negative for CD3, CD10, CD21, CD23, BCL-6

23
Q

His example of markers in MALT lymphoma

A

CD20+, CD10-, CD5-, CD23-, cyclin D1-

24
Q

MALT lymphoma frequently with

A

H. pylori
treat H. pylori, get rid of Lymphoma sometimes
In other places (not stomach) too with other associated diseases

25
Q

Indolent NHLs

A

Follicular, MALT, marginal zone, SLL, etc (mycosis fungoides)

untreated can survive years
Not curable, wait to tx until sxs

26
Q

Aggressive NHLS

A

DLBC, mantle cell

untreated can survive months
sometimes curable
treat

27
Q

Very aggressive NHLs

A

Lymphoblastic, Burkitt, AID-related

untreated can survive weeks
curable in some
treat

28
Q

Hodgkin lymphoma

A

All types are variable survival in untreated, usually curable, treat

29
Q

solid organ transplant patients or other patients on immune suppression, particularly with the calcineurin inhibitors (tacrolimus & cyclosporine) or ATG, who develop lymphoma.

A

think of PTLPD (post-transplant lymphoproliferative disorder).
This is an EBV induced, polyclonal, expansion of B-cells. Why does it occur? The suppression of T-cells leads to a loss of suppression of B-cell proliferation.
It is treated by backing off on the immune suppression.

30
Q

T-cell lymphomas tested in the form of

A

mycosis fungoides

31
Q

MF/SS general principles

A

Not curable
Frequently relapse, but systemic involvement is uncommon
Treatment is UV light, radiation, topical or systemic

32
Q

systemic T cell lymphoma

A

These behave badly
Again, CHOP is often the first line treatment
No rituximab!
If CD 30+, then brentuximab vedotin as targeted therapy

33
Q

CD30+ monoclonal ab

A

brentuximab vedotin